Icon raises full-year revenue guidance on the back of a strong Q3 showing

Icon — the Dublin-based pharmaceutical services provider — has upped its full-year revenue guidance for the second time in as many months, on the back of a strong third-quarter showing.

The Nasdaq-listed firm — a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical devices sectors — yesterday reported a 19% annualised rise in revenues, for the three months to the end of September, to $340m (€246.5m).

The period also saw a 59% year-on-year boost in operating profit, to $33.2m. Net profit was up by 57%, compared to the same quarter last year, at $27.8m, with third-quarter earnings per share rising from 29c to 45c.